NEW YORK, March 3, 2021 /PRNewswire/ -- Vaxalto
Biotherapeutics, Inc. (www.vaxalto.com), a pre-clinical stage
biotechnology company focused on developing and commercializing
novel engineered immunotherapeutic oncolytic viruses, and Mount
Sinai Innovation Partners (MSIP), part of the Icahn School of
Medicine at Mount Sinai, have
partnered to develop novel cancer immunotherapies. Mount Sinai has granted an exclusive,
worldwide license to Vaxalto covering intellectual property and
technology related to an avian paramyxovirus (APMV) oncolytic virus
platform and novel immuno-modulator targeting the lymphatic system.
This technology forms the core of Vaxalto's proprietary, multimodal
therapeutic approach utilizing direct destruction of cancer cells,
vascular and immune system activation.
"We are delighted to be partnering with Mount Sinai to develop our novel viral
immunotherapy, which eliminates tumors following intra-tumoral
administration and leads to long-term protection from cancer
recurrence based on animal studies," said Dr. Mihaela Skobe, Vaxalto co-founder and Director,
Laboratory for Metastasis and Lymphatic Research, Department of
Oncological Sciences at Mount
Sinai.
Skobe is joined by Dr. Peter
Palese and Dr. Adolfo
Garcia-Sastre, also from the Icahn School of Medicine at
Mount Sinai, to form Vaxalto's
scientific leadership team.
"We look forward to this collaboration between Mount Sinai and Vaxalto, in an effort to
advance potential breakthrough therapies using a novel approach to
treating a range of cancers," said Dr. Erik
Lium, President, Mount Sinai Innovation Partners and
Executive Vice President and Chief Commercial Innovation Officer,
Mount Sinai Health System
About Mount Sinai Innovation Partners
Mount Sinai Innovation Partners (MSIP) is responsible for
driving the real-world application and commercialization of
Mount Sinai discoveries and
inventions, and the development of research partnerships with
industry. Our aim is to translate discoveries and inventions into
healthcare products and services that benefit patients and society.
MSIP is accountable for the full spectrum of commercialization
activities required to bring Mount
Sinai inventions to life. These activities include
evaluating, patenting, marketing and licensing new technologies
building research, collaborations and partnerships with commercial
and nonprofit entities, material transfer and confidentiality,
coaching innovators to advance commercially relevant translational
discoveries, and actively fostering an ecosystem of
entrepreneurship within the Mount
Sinai research and health system communities. For more
information, please visit www.ip.mountsinai.org or find MSIP
on LinkedIn, Twitter, Facebook, Medium, and YouTube.
About the Mount Sinai Health System
The Mount Sinai Health System is New
York City's largest academic medical system, encompassing
eight hospitals, a leading medical school, and a vast network of
ambulatory practices throughout the greater New York region. Mount Sinai is a national and international
source of unrivaled education, translational research and
discovery, and collaborative clinical leadership ensuring that we
deliver the highest quality care—from prevention to treatment of
the most serious and complex human diseases. The Health System
includes more than 7,200 physicians and features a robust and
continually expanding network of multispecialty services, including
more than 400 ambulatory practice locations throughout the five
boroughs of New York City,
Westchester, and Long Island. The Mount Sinai Hospital is
ranked No. 14 on U.S. News & World Report's "Honor Roll"
of the Top 20 Best Hospitals in the country and the Icahn School of
Medicine as one of the Top 20 Best Medical Schools in country.
Mount Sinai Health System hospitals are consistently ranked
regionally by specialty and our physicians are in the top 1% of all
physicians nationally by U.S. News & World Report.
For more information, visit https://www.mountsinai.org or
find Mount Sinai on Facebook,
Twitter and YouTube.
About Vaxalto
Vaxalto is a pre-clinical stage biotechnology company focused
on developing and commercializing novel engineered
immunotherapeutic oncolytic viruses. With our proprietary,
two-pronged approach utilizing direct destruction of cancer cells
and immune system activation, patients will be uniquely positioned
to defeat cancer. For more information, go to www.vaxalto.com.
View original
content:http://www.prnewswire.com/news-releases/vaxalto-biotherapeutics-and-mount-sinai-enter-into-exclusive-license-agreement-for-the-development-and-commercialization-of-novel-immunotherapeutic-oncolytic-viruses-for-treatment-of-cancer-301239166.html
SOURCE Vaxalto Biotherapeutics, Inc.